UT-MD Anderson Cancer Center: Combined Delivery of Engineered Virus With Immunotherapy is Safe and Improves Outcomes in Subset of Patients With Glioblastoma
May 16, 2023
May 16, 2023
HOUSTON, Texas, May 16 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on May 15, 2023:
* * *
Study validates safety of combination approach, offering possibilities to adapt treatment strategies to optimize outcomes
* * *
Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent immunotherapy was safe and improved survival outco . . .
* * *
Study validates safety of combination approach, offering possibilities to adapt treatment strategies to optimize outcomes
* * *
Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent immunotherapy was safe and improved survival outco . . .